Steven R Alberts

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint OncoSurge: a strategy for long-term survival in metastatic colorectal cancer
    S Alberts
    Mayo Clinic, Rochester, MN 55905, USA
    Colorectal Dis 5:20-8. 2003
  2. pmc Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial
    Steven R Alberts
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Am J Clin Oncol 35:418-23. 2012
  3. doi request reprint Update on the optimal management of patients with colorectal liver metastases
    Steven R Alberts
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Crit Rev Oncol Hematol 84:59-70. 2012
  4. pmc Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973-2007
    Steven R Alberts
    Division of Medical Oncology, Go 10, Mayo Clinic, Rochester, MN 55905, USA
    Int J Circumpolar Health 71:17521. 2012
  5. pmc Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial
    Steven R Alberts
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    JAMA 307:1383-93. 2012
  6. doi request reprint Chemotherapy for colorectal cancer liver metastases
    Steven R Alberts
    Mayo Clinic, Rochester, Minnesota 55901, USA
    Oncologist 13:1063-73. 2008
  7. ncbi request reprint Therapeutic Advances in GI Malignancies--Fifth Annual Conference. 13-14 July 2007, Newport Beach, CA, USA
    Steven R Alberts
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    IDrugs 10:693-5. 2007
  8. ncbi request reprint Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:572-7. 2007
  9. ncbi request reprint Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial
    Steven R Alberts
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Oncol 22:4944-50. 2004
  10. ncbi request reprint Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial
    Steven R Alberts
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 103:111-8. 2005

Detail Information

Publications93

  1. ncbi request reprint OncoSurge: a strategy for long-term survival in metastatic colorectal cancer
    S Alberts
    Mayo Clinic, Rochester, MN 55905, USA
    Colorectal Dis 5:20-8. 2003
    ....
  2. pmc Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial
    Steven R Alberts
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Am J Clin Oncol 35:418-23. 2012
    ..Few effective options are available for the treatment of unresectable hepatocellular carcinoma (HCC). Several phase I trials suggest promising activity of a combination of gemcitabine and docetaxel...
  3. doi request reprint Update on the optimal management of patients with colorectal liver metastases
    Steven R Alberts
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Crit Rev Oncol Hematol 84:59-70. 2012
    ..Optimization of local therapies and systemic conversion strategies via controlled, randomized trials is still a pending question...
  4. pmc Occurrence of pancreatic, biliary tract, and gallbladder cancers in Alaska Native people, 1973-2007
    Steven R Alberts
    Division of Medical Oncology, Go 10, Mayo Clinic, Rochester, MN 55905, USA
    Int J Circumpolar Health 71:17521. 2012
    ..To describe the occurrence of pancreatic, biliary tract, and gallbladder cancers within the Alaska Native (AN) population. Study design: Population-based analysis utilizing a tumor registry and comparative population data...
  5. pmc Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial
    Steven R Alberts
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    JAMA 307:1383-93. 2012
    ..Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is the standard adjuvant therapy for resected stage III colon cancer. Adding cetuximab to FOLFOX benefits patients with metastatic wild-type KRAS but not mutated KRAS colon cancer...
  6. doi request reprint Chemotherapy for colorectal cancer liver metastases
    Steven R Alberts
    Mayo Clinic, Rochester, Minnesota 55901, USA
    Oncologist 13:1063-73. 2008
    ....
  7. ncbi request reprint Therapeutic Advances in GI Malignancies--Fifth Annual Conference. 13-14 July 2007, Newport Beach, CA, USA
    Steven R Alberts
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    IDrugs 10:693-5. 2007
  8. ncbi request reprint Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:572-7. 2007
    ..A phase I trial was performed to establish the maximum tolerated dose (MTD) of pemetrexed and oxaliplatin when B(12) and folate supplementation is used...
  9. ncbi request reprint Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial
    Steven R Alberts
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Oncol 22:4944-50. 2004
    ..ISIS-2503 is an antisense compound directed against H-ras with preclinical activity against pancreatic ACA in tumor models. The combination of ISIS-2503 and gemcitabine has been evaluated in a prior phase I study...
  10. ncbi request reprint Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial
    Steven R Alberts
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 103:111-8. 2005
    ....
  11. ncbi request reprint Treatment options for hepatobiliary and pancreatic cancer
    Steven R Alberts
    Division of Medical Oncology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:628-37. 2007
    ..For pancreatic cancer, surgery, radiation, and systemic therapy all have potential roles. This review provides an updated summary of diagnosis and assessment together with treatment options for this group of cancers...
  12. ncbi request reprint N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer
    Steven R Alberts
    Department of Medical Oncology, North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 5:211-3. 2005
  13. ncbi request reprint PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study
    S R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905
    Ann Oncol 16:1654-61. 2005
    ..This randomized phase II study determined the tumor response rate (RR) for PS-341 alone and the 6-month survival and RR for the combination of gemcitabine and PS-341 in patients with metastatic pancreatic adenocarcinoma...
  14. ncbi request reprint Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 23:9243-9. 2005
    ..The use of neoadjuvant chemotherapy to improve the likelihood of resection in disease that is not optimally resectable has not been as well studied...
  15. ncbi request reprint Occurrence of esophageal and gastric cancer in Alaska Natives, 1969-2003
    Steven R Alberts
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Alaska Med 48:2-11. 2006
    ..Early reports of esophageal and gastric cancer in American Indians/Alaska Natives documented high rates...
  16. ncbi request reprint Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trial
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Ther 13:291-7. 2006
    ..Quality-of-life measures did not show any differences between the 2 groups. This study showed no evidence of benefit from flutamide as a chemoprevention agent in men with HGPIN...
  17. doi request reprint Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Gastrointest Cancer 38:87-94. 2007
    ..To determine the maximum tolerated dose (MTD) and efficacy of pemetrexed and gemcitabine in patients with either biliary tract or gallbladder carcinoma...
  18. ncbi request reprint Updated options for liver-limited metastatic colorectal cancer
    Steven R Alberts
    Mayo Clinic, Division of Medical Oncology, Rochester, MN 55905, USA
    Clin Colorectal Cancer 7:S58-62. 2008
    ..Further trials are needed to refine the use of chemotherapy and targeted agents in the management of patients with liver metastases...
  19. ncbi request reprint Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study
    S R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 13:553-7. 2002
    ..The study was performed to determine the maximum tolerated dose (MTD) of gemcitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma (ACA)...
  20. pmc Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-
    Steven R Alberts
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 28:853-8. 2010
    ..However, the merits of this approach need to be established with a phase III trial...
  21. ncbi request reprint Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study
    S R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 14:580-5. 2003
    ..This study was performed to determine the efficacy of gemcitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma (ACA)...
  22. ncbi request reprint Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    J Gastrointest Cancer 38:10-4. 2007
    ..Currently no effective therapies exist for patients with advanced or metastatic HCC. KW-2189, a DNA minor groove-binding agent, has shown promising activity against HCC in preclinical evaluations...
  23. ncbi request reprint CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Gastrointest Cancer 32:107-14. 2002
    ..These cancers are typically refractory to standard chemotherapy agents. Based on preclinical work showing activity of CPT-11, we performed a phase II trial to assess its activity in patients with bile-duct or gallbladder carcinomas...
  24. ncbi request reprint Intrahepatic therapy for resected hepatic metastases from colorectal carcinoma
    S R Alberts
    Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 14:48-51. 2000
    ..Given the promising activity of oxaliplatin (Eloxatin), 5-FU, and leucovorin, a trial is now in development to assess the efficacy of this combination when used together with hepatic artery infusion...
  25. doi request reprint Treatment advances in liver-limited metastatic colorectal cancer
    Steven R Alberts
    Division of Medical Oncology, Mayo Clinic, Rochester, MN55905, USA
    Clin Colorectal Cancer 10:258-65. 2011
    ..Continued research to develop new and more active therapies, including targeted or biologic agents, is needed. This review discusses the advances made in management of patients with liver-limited metastatic disease...
  26. ncbi request reprint Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B)
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thorac Oncol 3:516-20. 2008
    ....
  27. ncbi request reprint A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies
    Cynthia Ma
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 59:207-15. 2007
    ..Two different treatment schedules of bortezomib in combination with paclitaxel and carboplatin were tested in this phase I study to evaluate the effects of scheduling on toxicities, pharmacodynamics and clinical activity...
  28. ncbi request reprint Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044)
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 30:507-13. 2007
    ..This study tested a 3-drug, multimodality approach. Chemotherapy dose reductions, the addition of amifostine, and pharmacogenetics were tested in an effort to mitigate toxicity and predict outcomes...
  29. ncbi request reprint Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741
    Grace K Dy
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 25:3469-74. 2007
    ..To evaluate clinical characteristics and survival outcomes among patients with locally advanced or metastatic colorectal cancer who achieve a complete response (CR) to systemic treatment either alone or with multimodality approach...
  30. ncbi request reprint A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
    Grace K Dy
    Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 55:522-30. 2005
    ..The present study was undertaken to evaluate the efficacy, toxicity, and pharmacokinetics of gemcitabine and pemetrexed when pemetrexed is administered immediately after gemcitabine...
  31. ncbi request reprint Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942
    Michael G Haddock
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:2567-72. 2007
    ..A phase II study was conducted to determine the efficacy and toxicity of radiotherapy with concomitant gemcitabine and cisplatin for patients with locally advanced pancreatic adenocarcinoma...
  32. ncbi request reprint Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials
    Aminah Jatoi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Int J Oncol 36:601-6. 2010
    ..Although age should not preclude trial entry, these adverse event rates suggest a need to develop more tolerable regimens for older patients with these malignancies...
  33. pmc Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma
    David J Rea
    Division of Gstroenterologic and General Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA
    Ann Surg 242:451-8; discussion 458-61. 2005
    ..Compare survival after neoadjuvant therapy and liver transplantation with survival after resection for patients with hilar CCA...
  34. ncbi request reprint A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin
    Julian R Molina
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Anticancer Drugs 16:997-1002. 2005
    ..However, the combination of BAY, VP-16 and CDBCA produces significant hematologic toxicity. Findings from this study may help to direct further studies with other inhibitors of MMPs...
  35. pmc Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy
    Frank A Sinicrope
    Frank A Sinicrope, Michelle R Mahoney, Thomas C Smyrk, Stephen N Thibodeau, Garth D Nelson, Daniel J Sargent, and Steven R Alberts, Mayo Clinic, Mayo Cancer Center and the North Central Cancer Treatment Group, Rochester, MN Robert S Warren, University of California San Francisco, San Francisco, CA Monica M Bertagnolli, Brigham and Women s Hospital, Boston, MA and Richard M Goldberg, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    J Clin Oncol 31:3664-72. 2013
    ..The association of deficient DNA mismatch repair (dMMR) with prognosis in patients with colon cancer treated with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remains unknown...
  36. ncbi request reprint A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer
    Alex A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:115-23. 2003
    ..The purpose of this study was to define the toxicity, pharmacokinetics, and clinical activity of the combination of ISIS 2503, an oligodeoxynucleotide antisense inhibitor of H-ras, and gemcitabine in patients with advanced solid tumors...
  37. ncbi request reprint Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma
    Julie K Heimbach
    William J von Liebig Transplant Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Transplantation 82:1703-7. 2006
    ..We reviewed our experience with the aim to identify clinicopathological predictors of disease recurrence...
  38. ncbi request reprint Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma
    Hendrik T J Mantel
    William J von Liebig Transplant Center, Department of Radiology, Mayo Clinic Rochester and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Liver Transpl 13:1372-81. 2007
    ..Liver transplantation with neoadjuvant therapy is associated with far higher rates of late arterial and portal venous complications, but these complications do not adversely affect patient and graft survival...
  39. ncbi request reprint A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Gastrointest Cancer 32:115-23. 2002
    ..With the emergence of data to suggest that single agent docetaxel and irinotecan carry antineoplastic effects in this setting, we determined the response rate of these agents when given in combination...
  40. ncbi request reprint Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
    Amanda C Ashley
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:670-7. 2007
    ..Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofi-Aventis, Paris, France) combined with irinotecan (IROX) were examined in 383 patients enrolled on the IROX arm of Intergroup Study N9741...
  41. doi request reprint Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors
    Aminah Jatoi
    Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    J Thorac Oncol 5:1994-8. 2010
    ..Based on favorable preliminary clinical data and the need to identify effective, well-tolerated neoadjuvant regimens for patients with locally advanced esophageal cancer, this clinical trial was undertaken...
  42. ncbi request reprint A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer
    Alex A Adjei
    Division of Medical Oncology, Mayo Clinic, Mayo Graduate School, Rochester, MN 55905, USA
    Invest New Drugs 20:297-304. 2002
    ..Subsequent studies revealed that PZA inhibits removal of platinum-DNA adducts in cultured A549 cells. Based on these results, we undertook a phase I study of the combination of PZA and carboplatin (CBDCA)...
  43. ncbi request reprint A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer
    Alex A Adjei
    Mayo Clinic and Foundation, Departments of Oncology and Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 9:2520-6. 2003
    ..This Phase I study was undertaken to define the toxicity, pharmacodynamics, and maximum tolerated dose of the combination of R115777, a farnesyl transferase inhibitor, with gemcitabine and cisplatin in patients with advanced solid tumors...
  44. ncbi request reprint Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy
    Thomas E Witzig
    Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:2606-17. 2005
    ..To determine whether weekly epoetin alfa could improve hemoglobin (HgB) levels, reduce RBC transfusions, and improve quality of life (QOL) in patients with advanced cancer and with anemia after receiving myelosuppressive chemotherapy...
  45. ncbi request reprint Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial
    Kostandinos Sideras
    Division of Hematology, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 81:758-67. 2006
    ..To prospectively assess whether low-molecular-weight heparin (LMWH) provides a survival benefit in patients with advanced cancer...
  46. ncbi request reprint A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer
    Grace K Dy
    Mayo Clinic, Rochester, Minnesota, 55905, USA
    Clin Cancer Res 11:3410-6. 2005
    ..To define the toxicities, pharmacodynamics, and clinical activity of the proteasome inhibitor, PS-341 (bortezomib), in patients with advanced malignancies...
  47. ncbi request reprint Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Sharlene Gill
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:1797-806. 2004
    ....
  48. ncbi request reprint Transplantation for hilar cholangiocarcinoma
    Julie K Heimbach
    William J von Liebig Transplant Center, Mayo Clinic College of Medicine, Rochester, MN, USA
    Liver Transpl 10:S65-8. 2004
    ..4. Survival following liver transplantation for unresectable, perihilar CCAs, mass lesion if present <3 cm, is greater than 80% at 5 years. 5. Patients with intrahepatic CCAs are not eligible for liver transplantation...
  49. pmc Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7
    Axel Grothey
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    J Clin Oncol 29:421-7. 2011
    ..In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT...
  50. ncbi request reprint Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer
    David P Steensma
    Mayo Clinic and Mayo Foundation, Rochester 55905, USA
    J Clin Oncol 24:1079-89. 2006
    ..To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia...
  51. ncbi request reprint A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors
    Henry C Pitot
    Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 58:165-72. 2006
    ..This phase I study evaluated the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of irinotecan given as a powder-filled capsule (PFC) daily for 5 days every 3 weeks...
  52. pmc Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer
    Evanthia Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 16:979-84. 2008
    ..5 months from treatment initiation. Rexin-G is well tolerated in doses up to 6 x 10(11) CFU in patients with recurrent pancreatic cancer, but there was no evidence of clinical antitumor activity...
  53. ncbi request reprint Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors
    Alex A Adjei
    Mayo Clinic and Foundation, Department of Oncology, Rochester, MN 55905, USA
    J Clin Oncol 20:1683-91. 2002
    ..To compare the pharmacokinetics of continuous venous infusion (CVI) fluorouracil (5-FU) with that of oral eniluracil/5-FU and to describe toxicities and clinical activity of prolonged oral administration of eniluracil/5-FU...
  54. pmc Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147
    Aminah Jatoi
    Mayo Clinic, Rochester, MN 55905, USA
    Oncology 77:120-3. 2009
    ..The objective of this study was to identify clinical predictors of severe rash in the hope of utilizing such factors in the design of future rash palliative and prevention trials...
  55. ncbi request reprint Metastatic colorectal cancer: Therapeutic options
    Smitha Patiyil
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Treat Options Oncol 7:389-98. 2006
    ..Patients with curative resection of metastatic disease seem to have longer DFS and better 5-year OS rates. This should be a potential goal for responding patients with upfront unresectable, organ-limited disease...
  56. ncbi request reprint KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF-Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
    Harry H Yoon
    Authors Affiliations Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota Lehigh Valley Hospital, Allentown, Pennsylvania and Ohio State University, Columbus, Ohio
    Clin Cancer Res 20:3033-43. 2014
    ..Analysis was restricted to BRAF-wild-type tumors, because BRAF mutation was associated with poor prognosis, and BRAF and KRAS mutations are mutually exclusive...
  57. ncbi request reprint A phase II study of topical ceramides for cutaneous breast cancer
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Breast Cancer Res Treat 80:99-104. 2003
    ..Short chain ceramides induce tumor cell apoptosis in preclinical models. Limited therapeutic options for patients with cutaneous breast cancer prompted the testing of these sphingolipids in patients with this disease...
  58. ncbi request reprint Liver transplantation for unresectable perihilar cholangiocarcinoma
    Julie K Heimbach
    William J von Liebig Transplant Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Semin Liver Dis 24:201-7. 2004
    ..Neoadjuvant chemoradiotherapy with liver transplantation achieves excellent results for patients with localized, regional lymph node negative, hilar cholangiocarcinoma...
  59. pmc Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma
    Sarwa Darwish Murad
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 56:972-81. 2012
    ..8; P = 0.01), portal vein encasement (HR 3.3; P = 0.007), and residual tumor on explant (HR 9.8; P < 0.001). Primary sclerosing cholangitis (PSC), age, history of cholecystectomy, and waiting time were not independent predictors...
  60. pmc Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers
    Frank A Sinicrope
    Division of Oncology, Mayo Clinic, Guggenheim 10 11C, 200 1st Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 14:4128-33. 2008
    ..We determined if expression of these proteins in colon cancers may account for differences in patient survival...
  61. ncbi request reprint Phase II trial of dolastatin-10 in patients with advanced breast cancer
    Edith A Perez
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Invest New Drugs 23:257-61. 2005
    ..Phase II multicenter cooperative group study investigated the efficacy and toxicity of the novel anti-microtubule agent dolastatin-10 in patients with advanced breast cancer...
  62. ncbi request reprint Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group
    Aminah Jatoi
    Mayo Clinic, Rochester, MN, 55905, USA
    Support Care Cancer 13:381-6. 2005
    ..The recent emergence of bortezomib, a proteasome inhibitor, now allows testing on whether proteasome inhibition is effective therapy for cancer-associated weight loss...
  63. ncbi request reprint A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin
    R M Goldberg
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Oncol 13:1674-80. 2002
    ....
  64. ncbi request reprint Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group
    K F Giordano
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 17:652-6. 2006
    ..We therefore undertook this phase II study to test this combination in a multi-institutional, first-line clinical trial...
  65. pmc Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)
    Kunal C Kadakia
    Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Cancer 118:2128-37. 2012
    ..To the authors' knowledge, this is the first randomized controlled trial to assess the efficacy of acitretin as a chemopreventive agent in nontransplantation patients at high-risk for NMSC...
  66. ncbi request reprint Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741
    T Delaunoit
    Department of Oncology, Cancer Center Statistics, Mayo Clinic, 200 First St Southwest, Rochester, MN 55905, USA
    Ann Oncol 16:425-9. 2005
    ..Here we identify and describe patients treated on Intergroup study N9741 who initially had inoperable MCRC, but who obtained sufficient chemotherapeutic benefit to allow removal of their metastatic disease...
  67. ncbi request reprint Phase II trial of KW2189 in patients with advanced malignant melanoma
    Svetomir N Markovic
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Am J Clin Oncol 25:308-12. 2002
    ..In summary, the lack of significant antitumor activity of KW-2189 and its associated toxicity suggest that further testing of this regimen in patients with stage IV melanoma is not warranted...
  68. doi request reprint Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer
    Michael G Haddock
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 79:143-50. 2011
    ..To evaluate survival, relapse patterns, and prognostic factors in patients with colorectal cancer relapse treated with curative-intent therapy, including intraoperative electron radiation therapy (IOERT)...
  69. ncbi request reprint Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study
    M Baweja
    Mayo Clinic, Jacksonville, FL 32224, USA
    Ann Oncol 17:623-9. 2006
    ..A one-stage phase II trial was conducted to assess the tumor response rate and toxicity profile of single agent oral vinorelbine as first or second-line chemotherapy for women at least 65 years of age with metastatic breast cancer...
  70. ncbi request reprint Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks
    S R Alberts
    Division of Medical Oncology and Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Oncol 12:627-31. 2001
    ..CONCLUSIONS: The maximum tolerated dose for this study recommended for phase II testing is gemcitabine 1000 mg/m2 and CPT-11 100 mg/m2. A partial response was seen in transitional cell carcinoma...
  71. ncbi request reprint Treatment endpoints for advanced cholangiocarcinoma
    Gregory J Gores
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nat Clin Pract Gastroenterol Hepatol 1:4-5. 2004
  72. doi request reprint Treatment of liver-limited metastatic colorectal cancer
    Joleen M Hubbard
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer J 16:235-40. 2010
    ..This review discusses the role of systemic therapy in patients with liver-limited metastatic disease for patients with resectable, potentially resectable and unresectable disease...
  73. pmc Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841
    George P Kim
    Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 27:2848-54. 2009
    ..Cross-over to the other treatment on disease progression was mandated...
  74. pmc Building a protocol expressway: the case of Mayo Clinic Cancer Center
    Terre A McJoynt
    Cancer Center Clinical Research Office, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:3855-60. 2009
    ..This results in dissatisfaction among sponsors, investigators, and staff and restricts the availability of novel treatment options for patients...
  75. ncbi request reprint Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity
    A A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN, USA
    J Clin Oncol 18:1116-23. 2000
    ....
  76. ncbi request reprint Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas
    R C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Esophagus 19:487-95. 2006
    ..For patients with isolated local recurrences, IORT may be effective salvage therapy. However, more effective systemic therapy is needed as a component of treatment...
  77. ncbi request reprint Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
    A A Adjei
    Department of Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 18:1748-57. 2000
    ..Multitargeted antifolate (MTA) is an investigational agent that, like gemcitabine, exhibits broad activity in solid tumors. A phase I trial of MTA and gemcitabine was undertaken, based on the demonstration of preclinical cytotoxic synergy...
  78. ncbi request reprint New adjuvant therapy for colon cancer: justified hope or commercial hype
    E Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Surg Oncol Clin N Am 9:813-23; discussion 825-6. 2000
    ..Future directions in the adjuvant treatment of colon cancer include incorporation of newer agents such as irinotecan, oxaliplatin, oral fluorinated pyrimidines, and immunotherapeutic approaches...
  79. ncbi request reprint Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566
    C Erlichman
    Mayo Clinic Cancer Center, Rochester, Minnesota, USA
    Ann Oncol 12:389-95. 2001
    ..We undertook a phase I study of BAY 12-9566, an inhibitor of MMP-2, MMP-9, and MMP-3, in patients with solid tumors to determine its safety, pharmacokinetics, and effects on potential surrogate markers of biologic activity...
  80. ncbi request reprint Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group
    A Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 17:29-34. 2006
    ..We therefore undertook this phase II study to test this first-line combination in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia...
  81. ncbi request reprint Impact of prognostic factors on clinical outcome after resection of colorectal pulmonary metastases
    Amanda C Ashley
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:32-7. 2006
    ..Pathologic markers that might determine outcome and current literature, which consists mainly of retrospective institutional reports, is reviewed...
  82. ncbi request reprint Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial
    Alvaro Moreno-Aspitia
    Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA
    Cancer 107:767-72. 2006
    ..Thalidomide has shown promise for the treatment of patients with myelodysplastic syndrome. The current prospective multicenter study examined the efficacy and toxicity of thalidomide in adult patients with myelodysplastic syndrome...
  83. ncbi request reprint High-folate diets and breast cancer survival in a prospective cohort study
    Thomas A Sellers
    Department of Health Sciences Research, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN 55905, USA
    Nutr Cancer 44:139-44. 2002
    ..These findings, although preliminary, afford some reassurance that folate supplementation is unlikely to have a significant adverse effect on survival after chemotherapy for breast cancer...
  84. ncbi request reprint Functional and clinical significance of variants localized to 8q24 in colon cancer
    Mine S Cicek
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street Southwest, 920 Hilton Building, Rochester, MN 55905, USA
    Cancer Epidemiol Biomarkers Prev 18:2492-500. 2009
    ..Finally, these risk alleles do not seem to be associated with survival...
  85. pmc A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu
    Prema P Peethambaram
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 15:5937-44. 2009
    ....
  86. ncbi request reprint Gastric cancer: epidemiology, pathology and treatment
    S R Alberts
    Mayo Clinic, Rochester, MN, USA
    Ann Oncol 14:ii31-6. 2003
    ..However, there is a pressing need for new agents, both cytotoxic and molecularly targeted, to be assessed in both the advanced and adjuvant settings...
  87. ncbi request reprint Pancreatic cancer in the older patient
    S D Jacobson
    Mayo Graduate School of Medicine, Rochester, Minnesota 55905, USA
    Oncology (Williston Park) 15:926-32; discussion 935-7. 2001
    ..For elderly patients with terminal disease, there should be better use of palliative measures that may be of benefit. Each of these issues is discussed in detail...
  88. pmc Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer
    A Gines
    Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
    Dis Esophagus 21:241-50. 2008
    ..With respect to the optimal treatment for each patient, agreement among physicians incrementally increases with endoscopic ultrasound results. Specialty training appears to influence therapeutic decision-making behavior...
  89. ncbi request reprint Evolving role of chemotherapy in resected liver metastases
    Steven R Alberts
    J Clin Oncol 24:4952-3. 2006
  90. ncbi request reprint A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:23-30. 2004
    ..In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease...
  91. ncbi request reprint Gemcitabine plus cisplatin in advanced pancreatic cancer
    Robert R McWilliams
    J Clin Oncol 25:1142; author reply 1142-3. 2007
  92. ncbi request reprint Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
    ..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...